 PDL BioPharma, Inc. PDL or the Company Nasdaq: PDLI announces the signing of a definitive agreement for the sale of 100 of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA collectively Noden to Stanley Capital Stanley Capital. The total value of the transaction will result in payments to PDL of up to 48.25 million in cash. 